Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes Clinical Trial

Official title:

A Phase I Study of Vosaroxin Plus Azacitidine for Patients With Myelodysplastic Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01913951
• Other study ID #: 201309091
• Status: Completed
• Phase: Phase 1
• Start date: November 22, 2013
• Est. completion date: April 29, 2024

Study information

• Verified date: April 2024
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial studies the side effects and the best dose of vosaroxin when given together with azacitidine in treating patients with myelodysplastic syndromes. Drugs used in chemotherapy, such as vosaroxin and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: April 29, 2024
• Est. primary completion date: December 5, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of myelodysplastic syndrome and one of the following:

• Cytopenias requiring red blood cell and/or platelet transfusions or neutropenia (ANC <1 X109/L)

• IPSS score of INT-1 or higher at screening

• MDS with excess blasts in transformation as defined by FAB criteria (20-29% bone marrow blasts) or

• Chronic myelomonocytic leukemia

• Age =18 years old

• Adequate renal and hepatic function defined as all of the following:

• total bilirubin = 2.0 mg/dl, except in cases of Gilbert's disease;

• AST and ALT =2.5 institutional ULN;

• serum creatinine within normal institutional limits or estimated creatinine clearance =60 mL/min/1.73 m2 by the Cockcroft-Gault equation

• ECOG performance status =2

• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

• Females must be surgically or biologically sterile or postmenopausal or if of childbearing potential, must agree to use an adequate method of contraception during the study until 30 days after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 30 days after the last treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

• Patients may have received up to 3 prior cycles of hypomethylator therapy (i.e. decitabine or azacitidine) prior to enrollment and may have received supportive care measures (growth factors, erythropoietin stimulating agents, transfusion, etc.

• Either enrolled in HRPO# 201011766 ("Tissue Acquisition for Analysis of Genetic Progression Factors in Hematologic Diseases"), which facilitates collection of blood, bone marrow, and skin for correlative studies, or consents to collection of blood, bone marrow, and skin as part of this protocol.

Exclusion Criteria:

• Prior treatment with four or more cycles of hypomethylator therapy.

• Receiving concomitant chemotherapy, radiation therapy, or immunotherapy during the duration of treatment on protocol.

• Known seropositivity for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible. Patients who are seropositive for HCV, but have a negative viral load are also eligible. Documentation that the patients have completed a course of therapy for HCV is required and will be obtained.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

• Pregnant and/or breastfeeding.

Related Conditions & MeSH terms

• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• vosaroxin
Given IV over 10 minutes on Day 1 and 4
• Azacitidine
Given SC or IV over 15 minutes on days 1-7

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
Washington University School of Medicine	Sunesis Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (1)

Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011 Dec;25(12):1808-14. doi: 10.1038/leu.2011.157. Epub 2011 Jul 15. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD of vosaroxin in combination with azacitidine	Defined as the highest dose of vosaroxin that results in a DLT in =< 1 of 6 patients graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 4.0	28 days
Secondary	Best response (including hematologic improvement)	According to the modified IWG criteria. Summarized as proportion with 95% confidence intervals.	At 3 cycles
Secondary	Best overall response	According to the modified IWG criteria. Summarized as proportion with 95% confidence intervals	Up to 7 months
Secondary	Incidence of adverse events	Graded according to NCI CTCAE v. 4.0. summarized by grade, type and patient.	Up to 7 months
Secondary	Time to response	According to the modified IWG criteria. Described using Kaplan-Meier models to plot these endpoints and estimate median times with a 95% confidence interval.	Up to 7 months
Secondary	Event-free survival	From the date of first dose of study drug to date of treatment failure, recurrence, or death due to any cause. Described using Kaplan-Meier models to plot these endpoints and estimate median times with a 95% confidence interval.	up to 5 years
Secondary	Progression-free survival (PFS)	From the date of first dose of study drug to disease progression or death from MDS. Described using Kaplan-Meier models to plot these endpoints and estimate median times with a 95% confidence interval.	up to 5 years
Secondary	Disease-free survival (DFS)	From the date of first documentation of a complete remission (CR) to date of relapse. Described using Kaplan-Meier models to plot these endpoints and estimate median times with a 95% confidence interval.	up to 5 years
Secondary	Overall survival (OS)	Date of first dose of study drug to the date of death from any cause. Described using Kaplan-Meier models to plot these endpoints and estimate median times with a 95% confidence interval.	up to 5 years
Secondary	Biomarkers of response to vosaroxin and azacitidine therapy	Serial estimate of biomarker expression will be plotted and summarized over time using means and standard deviations, possibly on a log scale	Up to 5 years

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine